Email updates

Keep up to date with the latest news and content from BMC Infectious Diseases and BioMed Central.

Open Access Research article

Genital warts and infection with human immunodeficiency virus in high-risk women in Burkina Faso: a longitudinal study

Andrea J Low1*, Tim Clayton1, Issouf Konate2, Nicolas Nagot3, Abdoulaye Ouedraogo1, Charlotte Huet2, Marie-Noelle Didelot-Rousseau3, Michel Segondy3, Philippe Van de Perre3, Philippe Mayaud12 and the Yérélon Cohort Study Group

Author Affiliations

1 London School of Hygiene & Tropical Medicine, London, UK

2 Centre Muraz, Bobo-Dioulasso, Burkina Faso

3 Université Montpellier 1, EA 4205 « Transmission, Pathogenèse et Prévention de l'Infection par le VIH »; and CHU Montpellier, Laboratoire de Bactériologie-Virologie and Département d'Information Médicale, Montpellier, France

For all author emails, please log on.

BMC Infectious Diseases 2011, 11:20  doi:10.1186/1471-2334-11-20

Published: 20 January 2011

Abstract

Background

Human papillomaviruses are the most common sexually transmitted infections, and genital warts, caused by HPV-6 and 11, entail considerable morbidity and cost. The natural history of genital warts in relation to HIV-1 infection has not been described in African women. We examined risk factors for genital warts in a cohort of high-risk women in Burkina Faso, in order to further describe their epidemiology.

Methods

A prospective study of 765 high-risk women who were followed at 4-monthly intervals for 27 months in Burkina Faso. Logistic and Cox regression were used to identify factors associated with prevalent, incident and persistent genital warts, including HIV-1 serostatus, CD4+ count, and concurrent sexually transmitted infections. In a subset of 306 women, cervical HPV DNA was tested at enrolment.

Results

Genital wart prevalence at baseline was 1.6% (8/492) among HIV-uninfected and 7.0% (19/273) among HIV-1 seropositive women. Forty women (5.2%) experienced at least one incident GW episode. Incidence was 1.1 per 100 person-years among HIV-uninfected women, 7.4 per 100 person-years among HIV-1 seropositive women with a nadir CD4+ count >200 cells/μL and 14.6 per 100 person-years among HIV-1 seropositive women with a nadir CD4+ count ≤200 cells/μL. Incident genital warts were also associated with concurrent bacterial vaginosis, and genital ulceration. Antiretroviral therapy was not protective against incident or persistent genital warts. Detection of HPV-6 DNA and abnormal cervical cytology were strongly associated with incident genital warts.

Conclusions

Genital warts occur much more frequently among HIV-1 infected women in Africa, particularly among those with low CD4+ counts. Antiretroviral therapy did not reduce the incidence or persistence of genital warts in this population.